Paper
A generative AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis: a randomized phase 2a trial
External resource. Not made or verified by Public Protocol.
Nature Medicine 2025 phase 2a trial of rentosertib in 71 patients over 12 weeks; the authors call for larger, longer trials.
https://doi.org/10.1038/s41591-025-03743-2
- Maintainer
- Xu and colleagues
- Licence, as stated at its source
- CC BY-NC-ND
- Open or commercial
- Not stated by the maker
- Maturity
- PrototypeOur reading, 16 November 2026
- Safety
- S3medical
- Review
- Listed 16 November 2026by Public Protocol editors
- Checked
- 16 November 2026
- Next check due
- 16 May 2027
- Steward
- Public Protocol editors
Where it sits in the blueprint
- Domains
- Stages
Learn
- Elements it supports
Recorded when its maker or a reviewer places it against single elements.
- Context
Climate, setting, scale, cost and skill: not stated in this entry. Check the source against your own place and numbers.
Verification
No verification is recorded on Public Platform for this entry. Records are added when someone reads it for accuracy, reviews it with a stated qualification, builds it or measures it.
Record
- How it came in
Seed catalogue, 16 November 2026. Listed from Praecise open research. The source was opened and described on the date shown.
- Licence
CC BY-NC-ND. Read at https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:40461817%20AND%20SRC:MED&resultType=core&format=json. How licences are recorded
- Something wrong?